An interventional study of Blood, nasopharyngeal swab and saliva and EBNA1-IgA, VCA-IgA, P85-Ab and EBV DNA in Nasopharyngeal Carcinoma (NPC), Screening and Epstein Barr Virus, sponsored by Ming-Yuan Chen. Recruiting at 1 site in China. Open to participants aged 30 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-11.
Sponsored by Ming-Yuan Chen · Not applicable, Interventional, and Screening
This study is a prospective, self-controlled, multicenter clinical trial. All participants will be tested for Epstein-Barr virus (EBV) associated biomarkers, including the two-antibody method (VCA-IgA and EBNA1-IgA), BNLF2b total antibodies (P85-Ab), and plasma EBV DNA. Furthermore, novel screening biomarkers, such as next-generation sequencing for EBV and castoff cells using nasopharyngeal swabs, will be explored.
First, it aims to investigate whether plasma EBV DNA testing or the P85-Ab testing can achieve higher sensitivity than the current standard two-antibody method testing while maintaining specificity in NPC screening, thereby identifying the optimal initial NPC screening strategy. Based on the determined optimal initial screening strategy, the study will validate the proposed two-step method (subjects first undergo two-antibody method testing and P85-Ab testing; those positive for either one biomarker above proceed to plasma EBV DNA testing; subjects positive in both steps are defined as high-risk and receive endoscopic examinations with or without biopsy) compared with the single-step method (subjects simultaneously undergo two-antibody method testing, P85-Ab testing, and plasma EBV DNA testing; subjects with any positive biomarker undergo endoscopic examinations with or without biopsy) and each single screening testing. The aim is to determine whether two-step method can further improve the positive predictive value (PPV) while maintaining non-inferior sensitivity, thereby enhancing screening efficiency, reducing the rate of invasive procedures (such as endoscopic biopsies), and lowering medical costs and insurance burdens.
159 studies on the registry are indexed under Epstein-Barr Virus Infections; 55 are open to participants now.
This study's planned enrollment of 68,649 is above the median of 28 across 105 interventional studies indexed under Epstein-Barr Virus Infections.
Browse Epstein-Barr Virus Infections studies →Ming-Yuan Chen is the lead sponsor of 12 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants aged between 30 and 69 years old.
Biological: Blood, nasopharyngeal swab and saliva · Diagnostic Test: EBNA1-IgA, VCA-IgA, P85-Ab and EBV DNA · Diagnostic Test: Novel screening biomarkers · Diagnostic Test: Endoscopic examinations with or without biopsy
Collect blood, nasopharyngeal swab and saliva samples from participants.
Detect EBNA1-IgA, VCA-IgA, P85-Ab and EBV DNA for all participants.
Next-generation sequencing for EBV and castoff cells using nasopharyngeal swabs, etc..
High-risk participants will refer to endoscopic examinations with or without biopsy
Sensitivity and specificity of EBV DNA testing, P85-Ab testing and the two-antibody method testing
To investigate whether plasma EBV DNA testing or the P85-Ab testing can achieve higher sensitivity than the current standard two-antibody method testing while maintaining specificity in NPC screening. Sensitivity refers to the proportion of actual positive cases (true positives) correctly identified by a test.
Time frame: At screening, 3 years and 10 years thereafter.
Sensitivity and positive predictive value (PPV) of the two-step method, single-step method and each single screening testing.
To determine whether two-step method can further improve the positive predictive value (PPV) while maintaining non-inferior sensitivity. PPV refers to the proportion of positive test results that are true positives. Sensitivity refers to the proportion of actual positive cases (true positives) correctly identified by a test.
Time frame: At screening, 3 years and 10 years thereafter.
Negative predictive value (NPV)
NPV refers to the proportion of positive negative results that are true negatives.
Time frame: At screening, 3 years and 10 years thereafter.
Early diagnosis rate of nasopharyngeal carcinoma
The proportion of nasopharyngeal carcinoma patients diagnosed at stages I and II according to the 9th version of AJCC TNM system.
Time frame: At screening, 3 years and 10 years thereafter.
Number needed to screen (NNS)
NNS refers to the amount of screening participants to identify one nasopharyngeal carcinoma case.
Time frame: At screening, 3 years and 10 years thereafter.
Nasopharyngeal Carcinoma Death Rates
Nasopharyngeal Carcinoma deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study.
Time frame: At screening, 3 years and 10 years thereafter.
Death Rates From All Causes
Deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study.
Time frame: At screening, 3 years and 10 years thereafter.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Epstein-Barr Virus Infections→
Ming-Yuan Chen